業績案内
研究案内へ

  • 2015年の主な業績
  • 2014年の主な業績
  • 2013年の主な業績
  • 2012年の主な業績
  • 2011年の主な業績
  • 過去の詳細な業績
◆ 原著論文

1) Suzuki N, Mihara H, Nishizono H, Tominaga M, Sugiyama T. Protease-Activated Receptor-2 Up-Regulates Transient Receptor Potential Vanilloid 4 Function in Mouse Esophageal Keratinocyte. Dig Dis Sci. 2015 Dec;60(12):3570-8.

2) Muhammad JS, Zaidi SF, Shaharyar S, Refaat A, Usmanghani K, Saiki I, Sugiyama T. Anti-inflammatory effect of cinnamaldehyde in Helicobacter pylori induced gastric inflammation. Biol Pharm Bull. 2015 Jan;38(1):109-15.

3) Kajiura S, Hosokawa A, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T. Effective healing of endoscopic submucosal dissection-induced ulcers by a single week of proton pump inhibitor treatment: a retrospective study. BMC Res Notes. 2015 Apr 15;8:150.

4) Ando T, Yoshita H, Ueda A, Kajiura S, Mihara H, Nanjo S, Fujinami H, Nishikawa J, Ogawa K, Nakajima T, Imura J, Sugiyama T. Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma. Gastroenterol Res Pract. 2015 Jun;2015:425876.

5) Wada A, Ito A, Iitsuka H, Tsuneyama K, Miyazono T, Murakami J, Shibahara N, Sakurai H, Saiki I, Nakayama T, Yoshie O, Koizumi K, Sugiyama T. Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments. Oncol Rep. 2015 Jun;33(6):2935-9.

6) Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res. 2015 Jul;45(7):755-63.

7) Fujinami H, Kajiura S, Ando T, Mihara H, Hosokawa A, Sugiyama T. Direct spraying of shakuyakukanzoto onto the duodenal papilla: a novel method for preventing pancreatitis following endoscopic retrograde cholangiopancreatography. Digestion. 2015 Jan;91(1):42-5.


◆ 症例報告

1) Tajiri K, Nakajima T, Kawai K, Minemura M, Sugiyama T. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma. Intern Med. 2015 Jan;54(6):597-600.

2) 田尻和人,河合健吾,峯村正実,長田拓哉,杉山敏郎.GIST肝転移術後再発に対してRFA治療を行った1例.医学と薬学.2015 Jan;72(2):260-3.

3) 西川 潤,細川 歩,明石桃子,三原 弘,南條宗八,吉田啓紀,安藤孝将,梶浦新也,藤浪 斗,杉山敏郎.抗TNF-α製剤投与によりIgA血管炎を発症したクローン病の1例.日本消化器病学会雑誌.2015 Oct;112(10):1852-7.


◆ 総  説

1) Sugiyama T. Progress in new diagnosis and therapeutic strategy for gastrointestinal malignancy: focus on new molecular-targeted treatments. Digestion. 2015 Jan;91(1):7-12.

2) Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol. 2015 Feb 14;21(6):1691-702. 3) Tajiri K, Shimizu Y. Unsolved problems and future perspectives of hepatitis B virus vaccination. World J Gastroenterol. 2015 Jun 21;21(23):7074-83.

4) Arita K, Tsuzuki S, Ohshima K, Sugiyama T, Seto M. Mouse model of mature B-cell lymphoma using in vitro retroviral gene-transduction systems. Cytometry Research. 2015 Feb;25(2):15-9. [Article in Japanese]

5) 加藤智惠子,杉山 敏郎.Helicobacter pyloriの感染診断と除菌判定.【H.pylori感染胃炎の診断と治療】日本消化器病学会雑誌.2015 Jun;112(6):994-9.

6) 杉山敏郎.酸関連疾患治療薬の有用性,防御因子増強薬.【酸関連疾患-最新の診断・治療動向-】日本臨床.2015 Jul ;73(7):1147-52.

7) 三原 弘.急性腹症の鑑別診断とピットフォール.【急性腹症の最新の基本知識】消化器外科.2015 Oct;38(11):1561-8.

8) 杉山敏郎.GIST診断と治療のポイント.消化管疾患のトピックス.MEDICAMENT NEWS. 2015 Nov;2214:4-5.


◆ 学会報告

1) Tajiri K. Analysis of hepatitis B virus using monoclonal antibodies obtained by the ISAAC method. 3rd JAPAN-TAIWAN Research Symposium on Hepatitis B virus; 2015 Apr 11-12; Tokyo.

2) Tajiri K, Kawai K, Minemura M, Yasumura S, Takahara T, Sugiyama T. Neutrophil/lymphocyte ratio does not predict the recurrence after curative treatment with radiofrequency ablation for small hepatocellular carcinoma. The 6th Asia-Pacific Primary Liver Cancer Expert Meeting(APPLE); 2015 Jul 3-5; Osaka.

3) Mihara H, Fujinami H, Yoshita H, Nanjyo S, Ando T, Kajiura S, Miura Y, Hosomkawa Y, Sugiyama T. Retrospective evaluation of the strategy for OGIB in a Japanese single university hospital. Asian Pacific Digestive Week; 2015 Dec 3-6; Taipei.

4) Fujinami H, Hosomkawa A, Miura Y, Kajiura S, Ando T, Mihara H,Nanjyo S,Yoshita H, Sugiyama T. Evaluation of the efficacy of hemostatic methods for peptic ulcer patients receiving anticoagulants: endoscopic clipping, hypertonic saline–epinephrine injection, and combination of the two. Asian Pacific Digestive Week; 2015 Dec 3-6; Taipei.

5) Nagata K, Fujinami H, Mihara H, Arita K, Murakami J, Wada A, Miyazono T, Sugiyama T. Utility of capsule endoscopy for detecting intestinal lesions of malignant lymphoma. Asian Pacific Digestive Week; 2015 Dec 3-6; Taipei.

6) 藤浪 斗,梶浦新也,安藤孝将,細川 歩,杉山敏郎.漢方研究の新たな展開 内視鏡的逆行性膵胆管造影(ERCP)前投薬としての芍薬甘草湯の有用性.漢方研究の新たな展開.第66回日本東洋医学会総会;2015 Jun 12-14:富山.(シンポジウム)

7) 三原 弘.中部消化管出血に関する原因や検査方法,診断や治療のコツ「パネルディスカッション」消化管出血の診断と対策.第105回日本消化器内視鏡学会北陸支部例会;2015 Jun 28;富山.

8) 河合健吾,田尻和人,高原照美.当院及び関連施設における急性肝炎症例の検討.「ワークショップ」急性肝炎の現状と問題点.第41回日本肝臓学会西部会;2015 Dec 3-4;名古屋.


◆ 原著論文

1) Arita K, Tsuzuki S, Ohshima K, Sugiyama T, Seto M. Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model. Leukemia. 2014 Nov;28(11):2270-2.

2) Yamawaki H, Mihara H, Suzuki N, Nishizono H, Uchida K, Watanabe S, Tominaga M, Sugiyama T. Role of transient receptor potential vanilloid 4 activation in indomethacin-induced intestinal damage. Am J Physiol Gastrointest Liver Physiol. 2014 Jul 1;307(1):G33-40.

3) Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res. 2014 Sep 5. doi: 10.1111/hepr.12417. [Epub ahead of print]

4) Yoshita H, Hosokawa A, Ueda A, Ando T, Kajiura S, Kato H, Kawabe H, Tomizawa G, Horikawa N, Yabuhita K, Note M, Sugiyama T. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases. Digestion. 2014;89(1):43-8.


◆ 症例報告

1) Nanjo S, Nishikawa J, Miwa S, Mihara H, Fujinami H, Yoshita H, Ueda A, Kajiura S, Hasumoto Y, Ando T, Hosokawa A, Sugiyama T. Immune-mediated protein-losing enteropathy with Down syndrome. Intern Med. 2014;53(20):2301-5.

2) Nishikawa J, Hosokawa A, Sugiyama T. Palatal ulcer as an initial manifestation of Crohn's disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):e115-6.

3) Tajiri K, Tsuneyama K, Atarashi Y, Kawai K, Minemura M, Sawada S, Tsukada K, Sugiyama T. A case of progressing focal nodular hyperplasia and its molecular expression pattern. Clin J Gastroenterol. 2014 Apr;7:271-7.

4) 吉田啓紀,細川 歩,中田直克,鈴木庸弘,南條宗八,植田 亮,金 辰彦,三原 弘,安藤孝将,藤浪 斗,梶浦新也,西川 潤,小川浩平,杉山敏郎.DCF療法が奏効し根治的化学放射線療法で完全奏効が得られた進行食道がんの1症例.腫瘍内科.2014;13(5):669-73.

◆ 総  説

1) Minemura M, Tajiri K, Shimizu Y. Liver involvement in systemic infection. World J Hepatol. 2014 Sep 27;6(9):632-42.

2) Tajiri K. CD1d-restricted Natural Killer T Cells in Metabolic Disorders. J Immun Res. 2014 Oct;1(2):4.

3) Tajiri K, Shimizu Y. The Contribution of Hepatic NKT Cells to the Pathogenesis of Nonalcoholic Fatty Liver Diseases. J Hepat Res. 2014 Sep;1(3):1013.

4) Tajiri K, Shimizu Y. Immunological aspects in drug-induced liver injury. World J Immunol 2014 Nov;4(3):149-57.

5) 杉山敏郎.消化管間質腫瘍(GIST)の分子標的治療.消化器がん化学療法の最先端.医学と薬学.2014;71(10):1775-82.

6) 細川 歩,吉田啓紀,中田直克,南條宗八,鈴木庸弘,植田 亮,金 辰彦,三原 弘,安藤孝将,藤浪 斗,梶浦新也,西川 潤,小川浩平,杉山敏郎.消化管の閉塞,穿孔,出血.オンコロジーエマージェンシー.癌の臨床.2014;60(1):41-6.

7) 三原 弘.H.pylori感染症と胃運動異常.機能性消化管障害の病態と治療.消化器内科.2014;58(2):184-8.

8) 吉田啓紀,杉山敏郎.胃悪性リンパ腫の診断と治療.悪性リンパ腫.保存版 消化器外科領域の希少悪性腫瘍.外科.2014;76(10):1083-7.

9) 加藤智惠子,杉山敏郎.胃炎への保険適用拡大後の留意点は?慢性胃炎保険適用後のHelicobacter pylori感染症診療の変化.Helicobacter Research.2014;18(4):334-8.

◆ 学会報告

1) Ueda A, Yuki S, Sasaki T, et al. Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002. Gastrointestinal Cancer Symposium; 2014 Jan 16-18; San Francisco.

2) Ando T, Hosokawa A, Nanjo S, Ueda Y, Akashi M, Ueda A, Mihara H, Kajiura S, Fujinami H, Nishikawa J, Sugiyama T: Comprehensive DNA methylation and extensive mutation analysis of gastric neuroendocrine carcinoma. Digestive Disease Week 2014; 2014 May 3-6; Chicago.

3) Mihara H, Suzuki N, Yamawaki H, Nishizono H, Tominaga M, Sugiyama T. TRPV2 knockout mice exhibit enhanced gastric emptying. Digestive Disease Week 2014; 2014 May 3-6; Chicago.

4) Arita K, Tsuzuki S, Ohshima K, Sugiyama T, Seto M. Synergy of Myc, cell cycle regulators and the Akt pathway in a mouse model of B-cell lymphoma. The 2014 American Society of Hematology (ASH) Meeting on Lymphoma Biology; 2014 Aug 10-13; Colorado Springs.

5) Tajiri K, Kawai K, Minemura M, Yasumura S, Sugiyama T. Neutrophil and lymphocyte ratio as a prognostic factor of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. The International Liver Cancer Association (ILCA) 2014; 2014 Sep 5-7; Kyoto.

6) Mihara H, Fujinami H, Tajiri K, Hosokawa A, Minemura M, Sugiyama T. PPI-induced suppression of TRPM6 and colonic H⁺,K⁺-ATPase expressed in colon epithelium can cause hypomagnesemia. 2014 Taiwan Digestive Disease Week; 2014 Oct 3-5; Kaohsiung.

7) Fujinami H, Kasashima M,Ando T, Hosokawa A, Sugiyama T. Characteristics of colorectal lesions according to the number of positive immunological fecal occult blood test results; A novel information for secondary screening. Digestive Disease Week 2014; 2014 May 3-6; Chicago.

8) 三原 弘,鈴木庸弘,杉山敏郎.機械刺激感受性のあるTRPV2イオンチャネルを欠損させたマウスの作出及び,その胃排出異常の検討.ワークショップ2:FGIDの病態生理学と脳腸相関研究の進歩.第100回日本消化器病学会総会;2014 Apr 23-26;東京.

9) 三原 弘,南條宗八,藤浪 斗,杉山敏郎.クローン病の治療強化,減弱に小腸用カプセル内視鏡は有用である.シンポジウム1「CEのクローン病への適応と安全性」.第7回日本カプセル内視鏡学会学術集会;2014 Jul 27;東京.

10) 三原 弘,藤浪 斗,杉山敏郎.PPI長期投与時に血清Mg測定は必要か.パネルディスカッション3 ,GERD―今何が問題とされているか(その争点);Japan Digestive Disease Week (JDDW) 第22回日本消化器病関連学会週間;2014 Oct 23-26;神戸.

◆ 原著論文

1) Sato Y, Inoue D, Asano N, Takata K, Asaoku H, Maeda Y, Morito T, Okumura H, Ishizawa S, Matsui S, Miyazono T, Takeuchi T, Kuroda N, Orita Y, Takagawa K, Kojima M, Yoshino T. Association between IgG4-related disease andprogressively transformed germinal centers of lymph nodes. Mod Pathol. 2012 Jul;25(7):956-67.(2012 年未掲載分)

2) Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T. Long-term follow-up outcome of imatinib mesylatetreatment for recurrent and unresectable gastrointestinal stromal tumors. Digestion. 2013;87(1):47-52.

3) Mihara H, Suzuki N, Yamawaki H, Tominaga M, Sugiyama T. TRPV2 ion channels expressed in inhibitory motor neurons ofgastric myenteric plexus contribute to gastric adaptive relaxation and gastric emptying in mice. Am J Physiol GastrointestLiver Physiol. 2013 Feb 1;304(3):G235-40.

4) Ueda A, Hosokawa A, Ogawa K, Yoshita H, Ando T, Kajiura S, Fujinami H, Kawai K, Nishikawa J, Tajiri K, Minemura M, Sugiyama T. Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial. Onco TargetsTher. 2013 May 8;6:491-6.

5) Arita K, Maeda-Kasugai Y, Ohshima K, Tsuzuki S, Suguro-Katayama M, Karube K, Yoshida N, Sugiyama T, Seto M.Generation of mouse models of lymphoid neoplasm using retroviral gene transduction of in vitro-induced germinal center Band T cells. Exp Hematol. 2013 Aug;41(8):731-41.

6) Miyazono T, Shiina T, Michino J, Yasumura S, Sugiyama T. A novel HLA-B allele, HLA-B*39:01:16, identified by superhigh-resolution single-molecule sequence-based typing in a Japanese individual. Tissue Antigens. 2013 Sep;82(3):205-6.

7) Murakami J, Matsui S, Ishizawa S, Arita K, Wada A, Miyazono T, Hounoki H, Shinoda K, Taki H, Sugiyama T. Recurrenceof IgG4-related disease following treatment with rituximab. Mod Rheumatol. 2013 Nov;23(6):1226-30.

8) Ueda A, Hosokawa A, Ogawa K, Yoshita H, Mihara H, Ando T, Kajiura S, Fujinami H, Nishikawa J, Minemura M, Terada M, Kobayashi T, Horikawa N, Yabushita K, Note M, Sugiyama T. Non-randomized comparison between irinotecan plusmitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.Anticancer Res. 2013 Nov;33(11):5107-11.

9) Ogawa K, Ueno T, Kato K, Nishitani H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Hosokawa A, Sugiyama T, Shimada Y. A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectalcancer patients. Int J Clin Oncol. 2013 Dec;18(6):1020-4.

10) Nishikawa J, Mihara H, Fujinami H, Nakajima T, Hosokawa A, Sugiyama T. Education and imaging. Gastrointestinal:Cobblestone in sigmoid volvulus. J Gastroenterol Hepatol. 2013 Jul;28(7):1072.

11) 元尾伊織,高原照美,松井恒志,ら.肝細胞癌との鑑別が画像上困難であった肝血管筋脂肪腫の2 例.肝臓.2013 Feb;54(2):143-51.

◆ 症例報告

1) Tajiri K, Tsuneyama K, Miyazono T, Kawai K, Minemura M, Sugiyama T. A Case of Primary Biliary Cirrhosis ThatProgressed Rapidly after Treatment Involving Rituximab. Case Rep Gastroenterol. 2013 Apr 19;7(1):195-201.

2) Nishikawa J, Mihara H, Sugiyama T. Systemic sclerosis in small bowel. Clin Gastroenterol Hepatol. 2013 Apr;11(4):A2

◆ 総  説

1) Sugiyama T. Proton pump inhibitors: Key ingredients in H.pylori eradication treatment. Frontiers of GastrointestinalResearch. 2013;31:59-67.

2) Murakami J, Shimizu Y. Hepatic manifestations in hematological disorders. Int J Hepatol. 2013 Mar 31;484903.

3) Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. World J Gastroenterol . 2013 Nov 21;19(43):7620-9.

4) Tajiri K, Shimizu Y. Liver physiology and liver diseases in the elderly. World J Gastroenterol. 2013 Dec 14;19(46):8459-67.

5) Muhammad JS, Sugiyama T, Zaidi SF. Gastric pathophysiological ins and outs of helicobacter pylori: a review. J Pak MedAssoc. 2013 Dec;63(12):1528-33.

6) 植田優子,安藤孝将,杉山敏郎.潰瘍性大腸炎における発癌リスクマーカーとしてのDNA メチル化異常.Medicine.2013 Mar;33(3):411-4.

7) 三原 弘,杉山敏郎.抗血栓薬/NSAIDs による消化管障害とそのマネージメント 薬剤性上部消化管障害におけるプロスタグランジン製剤・防御因子増強薬の効果と使い方.消化器の臨床.2013 Apr;16(2):186-90.

8) Faisal ZS,杉山敏郎.抗菌・抗炎症物質 各種植物・香辛料のHelicobacter pylori に対する抗菌・抗炎症作用.HelicobacterResearch.2013 Oct;17(5):430-41.

9) 安藤孝将,板谷優子,南條宗八,細川 歩,杉山敏郎.エピジェネティクス総論と胃癌におけるエピジェネティクス異常.Helicobacter pylori 感染胃粘膜のジェネティクス・エピジェネティクス.Helicobacter Res.2013;16:124-9.

◆ 学会報告

1) Ando T, Hosokawa A, Itaya Y, Yohita H, Ueda A, Mihara H, Fujinami H, Kajiura S, Nishikawa J, Ogawa K, Tsukioka Y,Kobayashi T, Horikawa N, Sugiyama T. Early decline of CA125 to chemotherapy in advanced gastric cancer with peritoneal effusion. 2013 Gastrointestinal Cancer Symposium; 2013 Jan 24-26; San Francisco.

2) Kajiura S, Hosokawa A, Nanjyo S, Yoshita H, Suzuki N, Yamawaki H, Ueda Y, Ueda A, Mihara H, Hasumoto Y, Ando T, Fujinami H, Nishikawa J, Ogawa K, Sugiyama T. Preventive effect of rikkunshito, traditional Japanese medicine, forchemotherapy-induced nausea and vomiting. Gastrointestinal Cancer Symposium; 2013 Jan 24-26; San Francisco.

3) Arita K, Tsuzuki S, Seto M. New mouse models of B-cell lymphoma using an in vitro retroviral transduction system. 9th AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research; 2013 Feb 21-25; Maui, HI.

4) Ando T, Ueda Y, Nanjo S, Mihara H, Fujinami H, Nishikawa J, Hosokawa A, Sugiyama T. DNA methylation of miR-124a could be individual risk marker of colitis-associated cancer in ulcerative colitis. Digestive Disease Week 2013; 2013 May 18-21; Orlando, FL.

5) Mihara H, Suzuki N, Ueda Y, Nanjo S, Ando T, Nishikawa J, Fujinami H, Hosokawa A, Tominaga M, Sugiyama T. Silencing of Transient Receptor Potential Vanilloid 4 (TRPV4) in gastric epithelium with its methylation could affect gastric emptying in H. pylori infected individuals. Digestive Disease Week 2013; 2013 May 18-21; Orlando, FL.

6) Yoshita H, Ando T, Hosokawa A, Ueda Y, Kajiura S, Ueda A, Nanjyo S, Hasumoto Y, Fujinami H, Nishikawa J, Ogawa K, Kobayashi T, Horikawa N, Ysukioka Y, Yabushita K, Sugiyama T. Favorable prognostic in advanced gastric cancer patients ineligible for criteria of the clinical trial. Digestive Disease Week 2013; 2013 May 18-21; Orlando, FL.

7) Murakami J, Kigawa M, Arita K, Wada A, Miyazono T, Ueda A, Yasumura S, Sugiyama T. The role of anticoagulant therapies on coagulopathy (disseminated Intravascular coagulation) in patients with patients with syndrome after Infection with enterohemorrhagic escherichia Coli O111. The 18th Congress of European Hematology Association. 2013 Jun 13-16; Stockholm.

8) Takahara T. IFN-γ deficiency attenuates hepatic inflammation and fibrosis in mouse steatohepatitis. 17th ISHSR & 27th HSRJ; 2013 Sep 23-25; Osaka.

9) Hosokawa A, Ando T, Yoshita H, Horikawa N, Yabushita K, Kawabe H, Tomizawa G, Kato H, Kashii T, Sugiyama T. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases. European Cancer Congress; 2013 Sep 27-Oct 1; Amsterdam.

◆ 原著論文

1) Ando T, Hosokawa A, Kajiura S, Itaya Y, Ueda A, Fujinami H, Nishikawa J, Kobayashi T, Horikawa N, Tsukioka Y, Yabushita K, Note M, Ogawa K, and Sugiyama T: Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy. Gastric Cancer, 15: 427-432, 2012.

2) Fujinami H, Kudo T, Hosokawsa A, Ogawa K, Miyazaki T, Nishikawa J, Kajiura S, Ando T, Ueda A, and Sugiyama T: A study of the changes in the cause of peptic ulcer bleeding. World J. Gastrointest. Endosc 4: 323-327, 2012.

3) Hosokawa A, Ogawa K., Ando T., Suzuki N, Ueda A, Kajiura S, Kobayashi Y, Tsukioka Y, Horikawa N, Yabushita K, Fukuoka J, and Sugiyama T: Preventive effect of traditional Japanese medicine on eurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Anticancer Res,32: 2545-2550, 2012.

4) Kawai K, Xue F, Takahara T, Kudo H, Yata Y, Zhang W, and Sugiyama T: Matrix metalloproteinase-9 contributes to the mobilization of bone marrow cells in the injured liver. Cell Transplant., 21: 453-464, 2012.

5) Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T, Ichinose M, Sugiyama T, and Ushijima T: Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer, 15: 382-388, 2012.

6) Ogawa K, Hosokawa A, Ueda A, Saito S, Mihara H, Ando T, Kajiura S, Terada M, Tsukioka Y, Horikawa N, Kobayashi T, Note M, Sawasaki K, Fukuoka J, and Sugiyama T: Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study. Gastroenterol. Res. Pract., 2012: Article ID 640401, 2012.

7) Yamada K, Sugiyama T, Mihara H, Kajiura S, Saito S, Itaya Y, Yamawaki H, Ando T, Kudo T, Hosokawa A, Okuda M, Fukunaga K, Akada J K, and Nakazawa T: Fragmented CagA protein is highly immunoreactive in Japanese patients. Helicobacter, 17: 187-192, 2012.

8) Zaidi S F, Muhammad J.S, Shahryar S, Usmanghani K, Gilani AH, Jafri W, and Sugiyama T:Anti-inflammatory and cytoprotective effects of selected Pakistani medicinal plants in Helicobacter pylori-infected gastric epithelial cells. J. Ethnopharmacol, 141: 403-410, 2012.

9) 田尻和人, 河合健吾, 時光善温, 安村 敏, 峯村正実, 高原照美, 杉山敏郎, 長田拓哉, 塚田一博 : 脾摘術を施行しインターフェロンを導入したC 型肝硬変7 症例の検討. 日本門脈圧亢進症学会雑誌, 18: 40-44, 2012.

10) 三原 弘, 岡津成祐, 和田暁法, 村上 純, 杉山敏郎, 野村英樹, 梶波康二 : 第1 回腹部救急診療トレーニングコース(AbdEMeT)の概要と評価結果. 日本内科学会雑誌, 101: 1112-1116, 2012.

◆ 症例報告

1) Nishikawa J, Tanaka T, and Sugiyama T: Melanosis ilei. Clin. Gastroenterol. Hepatol., 10: A24, 2012.

2) Tajiri K, Shimizu Y, Tokimitsu T, Tsuneyama K, and Sugiyama T: An elderly man with syncytial giant cell hepatitis successfully treated by immunosuppressants. Intern Med, 51: 2141-2144, 2012.

3) 西川 潤, 工藤俊彦, 宮嵜孝子, 三原 弘, 植田 亮, 安藤孝将, 梶浦新也, 藤浪 斗, 小川浩平, 細川 歩, 杉山敏郎 : チオプリン製剤投与により急性膵炎を発症した炎症性腸疾患の2 例. 日本消化器病學會雜誌, 109:224-230, 2012.

4) 中嶋隆彦, 飯原久仁子, 福島純一, 常山幸一, 齋藤聖子, 杉山敏郎, 堀内 啓 : 小網原発を模倣した壁外発育型胃GIST の1 例. 日本消化器病学会雑誌, 109: 1367-1371, 2012.

◆ 総  説

1) Tajiri K, and Shimizu Y: Role of NKT cells in the pathogenesis of NAFLD. Int. J. Hepa, 2012: 850836,2012.

2) 杉山敏郎 : 消化管原発悪性リンパ腫. 下部消化管,V.消化器疾患の診断と治療. 日本医師会雑誌, 141: S240-241,2012.

3) 杉山敏郎 : H2 受容体拮抗薬. Medicina, 49: 146-149, 2012.

4) 杉山敏郎 : 韓国と日本のHelicobacter researches 研究の類似点と相違点. Helicobacter Res, 16: 364-365,2012.

5) 安村 敏 : アルブミン製剤をどう使うか. Medicina, 49: 1233, 2012.

6) 藤浪 斗, 細川 歩, 小川浩平, 梶浦新也, 安藤孝将, 植田 亮, 吉田啓紀, 杉山敏郎 : 消化器内視鏡治療の新たな工夫/安全な食道ESD の取り組み. 消化器医学, 10: 12-15, 2012.

7) 安藤孝将, 板谷優子, 南條宗八, 細川 歩, 杉山敏郎 : エピジェネティクス総論と胃癌におけるエピジェネティクス異常. Helicobacter pylori 感染胃粘膜のジェネティクス・エピジェネティクス. Helicobacter Res, 16:124-129, 2012.

8) 三原 弘, 富永真琴 : TRPV チャネルについて何がわかっているか. 特集:消化器疾患の知覚受容機構の研究の進歩. 分子消化器病, 8: 6-11, 2011.

9) 三原 弘 : 消化管機能性疾患とTRP ファミリー. 消化器疾患のトピックス. THE GI FOREFRONT, 8: 74-78, 2012.

10) 吉田啓紀, 杉山敏郎 : 胃悪性リンパ腫. 診療の現状と展望. 日本臨床, 70: 1253-1262, 2012.

11) 板谷優子, 杉山敏郎 : 糖尿病と胃がん. 耐糖能異常・糖尿病と各種臓器がんの関連性. 糖尿病学の最新動向. 最新臨床糖尿病学・下. 日本臨床, 70:578-581, 2012.

12) 和田暁法, 杉山敏郎 : Helicobacter pylori と特発性血小板減少性紫斑病. 成人病と生活習慣病, 42: 1214-1217,2012.

◆ 学会報告

1) Ando T, Hosokawa A, Ogawa K, Kajiura S, Itaya Y, Ueda A, Tsukioka Y, Kobayashi T, Horikawa N, and Sugiyama T: Efficacy of weekly paclitaxel in advanced gastric cancer patients with prior docetaxelcontaining chemotherapy. 2012 Gastrointestinal Cancer Symposium, 2012, 1, 19-21, San Francisco.

2) Kajiura S, Hosokawa A, Yoshita H, Nakada N, Itaya Y, Ueda A, Ando T, Fujinami H, Ogawa K, and Sugiyama T: Preventive effect of rikkunshito, traditional Japanese medicine, for chemotherapy-induced nausea and vomiting. 2012 Gastrointestinal Cancers Symposium, 2012, 1, 19-21, San Francisco.

3) Fujinami H, Hosokawa A, Ogawa k, Nishikawa J, Kajiura S, Mihara H, Ando T, and Sugiyama T: Evaluation of the efficacy of hemostatic methods for peptic ulcer patients receiving anticoagulants: endoscopic clipping, hypwrtonic saline-epinephrine injection, and combination of the two. DDW2012, 2012, 5, 19-22, San Diego.

4) Mihara H, Suzuki1 N, Tominaga M, and Sugiyama T: TRPV2 ion channel expressed in inhibitory motor neurons of gastric myenteric plexus contributes gastric gdaptive relaxation and emptying. DDW2012, 2012, 5, 19-22, San Diego.

5) Suzuki N, Mihara H, Tominaga M, and Sugiyama T: Pancreatic enzyme, trypsin, increases the sensitivity of TRPV4 ion channel expressed in esophagus via PAR-2. DDW2012, 2012, 5, 19-22, San Diego.

6) Mihara H, Boudaka A, Suzuki N, Yamawaki H, Sugiyama T, Moriyama Y, and Tominaga M: TRPV4-mediated ATP exocytosis is enhanced by PAR-2 activation in mouse esophageal keratinocytes. International Symposium on Purinergic signalling Purine 2012, 2012, 5, 31 -6, 2, Fukuoka.

7) Kawai K, Luo X, Tsukada K, SugiyamaT, and Takahara T: MMP-9 ptomotes the trafficking of transplanted bone marrow cells that attenuates hepatic fibrosis in chronic CCL4 liver injury. ISSCR 10th Annual Meeting, 2012, 6, 13-16, Yokohama.

8) Suzuki N, Mihara H, Tominaga M, and Sugiyama T: The activation of Protease-activated receptor-2 (PAR-2) sensitizes Transient receptor potential vanilloid 4 (TRPV4) ion channel expressed in esophagus. The 14th Meeting of International Conference on Ulcer Research (ICUR2012) Symposium 3 "Chemosensing and Gut Hormones", 2012, 7, 12-14, Tokyo.

9) 三原 弘, 鈴木庸弘, 杉山敏郎 : H.pylori 感染による胃上皮TRPV4 イオンチャネルのメチル化が,胃機能異常の原因になり得る. シンポジウム14 機能性消化管障害の病態と治療, JDDW2012, 2012, 10, 10-13, 神戸.

10) 細川 歩 : 実臨床におけるHER2 陽性胃癌の治療(内科の立場から). 第50 回日本癌治療学会学術集会, 2012, 10, 25-27, 横浜.

◆ 原著論文

1) Wada A, Kobayashi N, Asanuma S, Matsuoka S, Kosugi M, Fujii S, Noguchi S, Miyazono T, Nakata M, Ota S, Imai K, Hirano T, Ogasawara M, Kiyama Y and Kasai M: Repeated donor lymphocyte infusions overcome a myeloid sarcoma ofthe stomach resulting from a relapse of acute myeloid leukemia after allogeneic cell transplantation in long-term survival ofmore than 10 years. Int. J. Hematol., 93: 118-122, 2011.

2) Ando T, Hosokawa A, Yamawaki H, Hasumoto Y, Kajiura S, Itaya Y, Ueda A, Suzuki N, Nishikawa J, Fujinami H, Miyazaki T, Ogawa K and Sugiyama T: Esophageal small-cell carcinoma with syndrome of inappropriate secretion ofantidiuretic hormone. Intern. Med., 50: 1099-1103. 2011.

3) Mihara H, Boudaka A, Sugiyama T, Moriyama Y, and Tominaga M: Transient receptor potential vanilloid 4(TRPV4)-dependent calcium influx and ATP release in mouse esophageal keratinocytes. J. Physiology, 589: 3471-3482, 2011.

◆ 症例報告

1) Nishikawa J, Funada H, Miyazaki T, Fujinami H, Miyazono T, Murakami J, Kudo T and Sugiyama T: Infectious mononucleosis with atypical manifestations accompanied by transient IgM antibody response for cytomegalovirus. J. Infect Chemother, 17: 686-688, 2011.

2) Ando T, Hosokawa A, Yamawaki H, Hasumoto Y, Kajiura S, Itaya Y, Ueda A, Suzuki N, Nishikawa J, Fujinami H, Miyazaki T, Ogawa K and Sugiyama T: Esophageal small-cell carcinoma with syndrome of inappropriate secretion ofantidiuretic hormone. Intern. Med., 50: 1099-1103, 2011.

3) Ueda A, Okada K, Takahara T, Iwasa K, Shinagawa K, Etani A, Inatsuchi S, Ando T, Fujinami H, Tajiri K, Tokimitsu Y,Ogawa K, Miyazono T, Myazaki T, Murakami J, Hosokawa A, Yasumura S, Minemura M, Kudo T and Sugiyama T: Acase of adult-onset type II citrullinemia induced by hospotal diet. Clin. J. Gastroenterol., 4: 28-33, 2011.

4) Ueda A, Fuse N, Fujii S, Sasaki T, Sugiyama J, Kojima T, Yoshino T, Tahara M, Doi T, Sugiyama T, and Ohtsu A:Plumonary Tumor Thrombotic Microangiopathy Associated with Esophageal Squamous Cell Carcinoma. Intern. Med., 50:2807-2810, 2011.

5) Nakajima T, Saito S, Sugiyama T, Murata K, Fukushima J, and Horiuchi H: Epithelioid gastrointestinal stromal tumor ofthe stomach mimicking extragastrointestinal origin. Pathol. Int, 61: 677-680, 2011.

6) Arita K, Kondo T, Sugita J, Shigematsu A, Shiratori S, Wakasa K, Yasumoto A, Ibata M, Shono Y, Kikuchi M, Goto H,Takeda Y, Takahata M, Kato N, Nishio M, Ota S, Tanaka J and Imamura M: Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Int. J. Hematol., 94: 291-295,2011.

7) 西川 潤,宮嵜孝子,鈴木庸弘,板谷優子,山脇秀元,三原 弘,蓮本祐史,藤浪 斗,小川浩平,細川 歩,工藤俊彦,杉山敏郎:infliximab 投与により薬剤誘発性ループスを発症した潰瘍性大腸炎の1 例.日消誌,180:1535-1539,2011.

◆ 総  説

1) 杉山敏郎:特集 続 他科医に聞きたいちょっとしたこと.Helicobacter pylori 感染に伴う生体の免疫反応(Q&A/特集).クリニシアン,58:703-705,2011.

2) 杉山敏郎:特集 上部消化管疾患の実地診療.セミナー/実地診療で活用すべき知識 H.pylori 除菌治療と薬剤耐性.Medical Practice,28:265-268,2011.

3) 杉山敏郎:特集 胃悪性腫瘍診療の新展開.胃悪性リンパ腫診療の新展開.日消誌,108:1528-1534,2011.

4) 杉山敏郎:特集 内科 疾患インストラクションガイド 何をどう説明するか.消化器疾患 NSAIDs 起因性消化性潰瘍.Medicina,48:202-205,2011.

5) 杉山敏郎:H.pylori 感染と胃がん・がん検診.日本消化器がん検診学会雑誌,49:275,2011.03

6) 板谷優子,杉山敏郎:特集 肥満・糖尿病と悪性腫瘍.糖尿病・肥満と胃癌.医学のあゆみ,237:761-764,2011.

7) 安藤孝将,加藤智恵子,杉山敏郎:第17 回日本ヘリコバクター学会学術集会<基礎から>.Helicobacter Research,15:89-91,2011.

◆ 学会報告

1) Hosokawa A, Ogawa K, Kajiura S, Tsukioka Y, Kobayashi T, Horikawa N, Kobayashi Y, Yoshioka A, Sumi S and Sugiyama T: A phase I/II study of S-1 plus cisplatin alternating with S-1 plus docetaxel in patients with advanced gastriccancer(AGC). 2011 Gastrointestinal Cancers Symposium, 2011, 1, 20-22, San Francisco.

2) Fujinami H, Kudo T, Hosokawa A, and Sugiyama T: Endoscopic submucosal dissection of superficial esophageal squamous cell neoplasia by scissors-like forceps: A safer technique. DDW2011, 2011, 5, 7-10, Chicago.

3) Mihara H, Boudaka A, Sugiyama T, Moriyama Y, and Tominaga M: Transient receptor potential vanilloid 4 dependent calcium influx and AP release in mouse esophageal keratinocytes. DDW2011, 2011, 5, 7-10, Chicago.

4) Ando T, Asada K, Niwa T, Yoshida T, Hosokawa A, Sugiyama T and Ushijima T: FHL1 on the X chromosome is a single-hit tumor-suppressor gene in gastric cancer and contributes to gastric carcinogenesis. 8th Japan-Korea Joint Conference on Helicobacter Infection, 2011, 5, 27, Seoul.

5) Tajiri K, Tokimitsu Y, Kawai K, Minemura M, Takahara T, Yasumura S, and Sugiyama T: Optimization timing of the treatment with sorafenib for advanced hepatocellular carcinoma. The 2nd ASIA-Pacific primary liver cancer expezrt meeting, 2011, 7,1-3, Osaka.

6) Kawai K, Tajiri K, Tokimitsu Y, Minemura M, Takahara T, Yasumura S, and Sugiyama T: Repeated radiofrequency ablation (RFA) for management of patients with intrahepatic distant reccurence (IDR) of hepatocellular carcinoma. The 2nd ASIA-Pacific primary liver cancer expezrt meeting, 2011, 7, 1-3, Osaka.

7) Murakami J, Arita K, Wada A, Miyazono T, Kawai K, Tajiri K, Tokimitsu Y, Minemura M, Yasumura S, Takahara T and Sugiyama T: Screening, monitoring and prophylaxis of the reactivation of hepatitis b virus infection in patients with malignant lymphomas on steroid- and rituximab-containing systemic chemotherapies. 2011 Pan Pacific Lymphoma Conference, 2011, 8, 15-19, 2011, Hawaii.

8) Murakami J, Matsui S, Ishizawa S, Arita K, Wada A, Miyazono T, Ogawa R, Hounoki H, Shinoda K, Taki H and Sugiyama T: Recurrence of IgG4-related systemic disease treated by rituximab. International Symposium on IgG4-Related Disease, 2011, 10, 4-7, Boston.

9) Takahara T, Kawai K, Luo X, Sugiyama T, Tsukada K, Asahi M and Michieli P: Magic-Factor, a partial agonist of Met,acts as a safe hepatotrophic cytokine. The 62th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD 2011, 2011, 11, 4-8, San Francisco.

現在準備中です

ヘ